Jon Price – Managing Director – Richmond Vanadium Technology (ASX:RVT) is an Australian minerals development company which is advancing the Richmond – Julia Creek Vanadium Project in Queensland through a Bankable Feasibility Study.
Copyright 2023 – Finance News Network
Source: Finance News Network
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
Read More17 Mar 2025 - LAG-3 and the Role of Immune Checkpoints in Cancer Treatment
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More30 Jul 2024 - Justin Virgin - Executive Director - Terrain Minerals (ASX:TMX) is a West Australian based minerals exploration company focused on the world class mineral provinces in Western Australia. Terrain is actively looking for opportunities within other states of Australia and internationally.
Read More18 May 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's pipeline and discusses the recent licensing of an asset from UCLA.
Read More21 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
Read More11 Jun 2024 - Glen Finegan, Lead Portfolio Manager of Skerryvore, discusses the company's bottom-up approach to investing in emerging markets, emphasising governance, pricing power, and diversification as key drivers of success.
Read More17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.
Read More02 Oct 2019 - Noxopharm Limited (ASX:NOX) Founder and Executive Chairman, Dr Graham Kelly, discusses early results on the use of Noxopharm's lead drug candidate, Veyonda, for the treatment of prostate cancer.
Read More21 Apr 2025 - Navigating the FDA Process and Clinical Trial Hurdles
Read More
